

# MARKET REPORT



## Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk)

# Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027

DelveInsight's "Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast, 2027" report provides a comprehensive analysis of the Metastatic Renal Cell Carcinoma (mRCC) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

## Markets Covered

- United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan

Study Period: 2016-2027

## Metastatic Renal Cell Carcinoma (mRCC) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Metastatic Renal Cell Carcinoma (mRCC) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Metastatic Renal Cell Carcinoma (mRCC) outlook. It also includes the explanation of changing trends of epidemiology outlining the Metastatic Renal Cell Carcinoma (mRCC) scenario.

## Metastatic Renal Cell Carcinoma (mRCC) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Metastatic Renal Cell Carcinoma (mRCC) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

## Report Scope

- The report covers detailed overview of Metastatic Renal Cell Carcinoma (mRCC) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
- The Metastatic Renal Cell Carcinoma (mRCC) Report assesses the disease risk and burden and highlights the unmet needs
- It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

## Key strengths

- 10 Year Forecast  
<https://www.bioportfolio.co.uk/product/201493>  
[pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk) to order

- 7MM Coverage
- Total Cases in Metastatic Renal Cell Carcinoma (mRCC)

#### Key assessments

- Patient Segmentation in Metastatic Renal Cell Carcinoma (mRCC)
- Metastatic Renal Cell Carcinoma (mRCC) Risk & Burden
- Factors driving growth in a specific Metastatic Renal Cell Carcinoma (mRCC) patient population

## Additional Details

**Publisher :** Delve Insight

**Reference :** DIEI0143

**Number of Pages :** 50

**Report Format :** PDF

**Publisher Information :**



**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

**DELVEINSIGHT**  
INSIGHT ACROSS SECTORS AND  
REGIONS

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

# Table Of Contents for Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

- 1. Report Introduction2. Metastatic Renal Cell Carcinoma (mRCC) Epidemiology Overview at a Glance2.1. Patient Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) in 20172.2. Patient Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) in 20273. Disease Background and Overview: Metastatic Renal Cell Carcinoma (mRCC) 3.1. Introduction3.2. Symptoms3.3. Etiology3.4. Risk Factors3.5. Pathophysiology3.6. Diagnosis3.7. Treatment4. Epidemiology and Patient Population4.1. Key Findings4.2. Total Prevalent/ Incident Patient Population of Metastatic Renal Cell Carcinoma (mRCC) in 7MM4.3. Total Prevalent/ Incident Patient Population of Metastatic Renal Cell Carcinoma (mRCC) in 7MM - By Countries5. Epidemiology of Metastatic Renal Cell Carcinoma (mRCC) by Countries5.1. United States5.1.1. Assumptions and Rationale5.1.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) 5.1.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.1.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.1.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) 5.2. EU5.3. Assumptions and Rationale5.4. Germany5.4.1. Assumptions and Rationale5.4.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) 5.4.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.4.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.4.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) 5.5. France5.5.1. Assumptions and Rationale5.5.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) 5.5.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.5.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.5.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) 5.6. Italy5.6.1. Assumptions and Rationale5.6.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) 5.6.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.6.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.6.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) 5.7. Spain5.7.1. Assumptions and Rationale5.7.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) 5.7.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.7.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.7.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) 5.8. United Kingdom5.8.1. Assumptions and Rationale5.8.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) 5.8.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.8.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.8.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) 5.9. Japan5.9.1. Assumptions and Rationale5.9.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) 5.9.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.9.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) \*5.9.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) 6. Unmet Needs of the Metastatic Renal Cell Carcinoma (mRCC) 7. Appendix8. Report Methodology8.1. Sources9. DelveInsight Capabilities10. Disclaimer11. About DelveInsight\*Indication Specific



# List Of Tables in Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

- Table 1: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM
- Table 2: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM by Countries
- Table 3: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)
- Table 4: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)\*
- Table 5: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)\*
- Table 6: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)
- Table 7: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)
- Table 8: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027) \*
- Table 9: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027) \*
- Table 10: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)
- Table 11: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)
- Table 12: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027) \*
- Table 13: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027) \*
- Table 14: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)
- Table 15: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)
- Table 16: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027) \*
- Table 17: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027) \*
- Table 18: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)
- Table 19: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)
- Table 20: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027) \*
- Table 21: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027) \*
- Table 22: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)
- Table 23: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)
- Table 24: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027) \*
- Table 25: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027) \*
- Table 26: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)
- Table 27: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Table 28: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027) \*

Table 29: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027) \*

Table 30: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

# List Of Figures, Charts and Diagrams in Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM

Table 2: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)\*

Table 5: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)\*

Table 6: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Table 7: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Table 8: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027) \*

Table 9: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027) \*

Table 10: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Table 11: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Table 12: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027) \*

Table 13: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027) \*

Table 14: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Table 15: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Table 16: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027) \*

Table 17: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027) \*

Table 18: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Table 19: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Table 20: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027) \*

Table 21: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027) \*

Table 22: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Table 23: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Table 24: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027) \*

Table 25: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027) \*

Table 26: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Table 27: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)



Table 28: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027) \*

Table 29: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027) \*

Table 30: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

# How to Buy...

Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/201493>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$3250** | Single User Price
- \$6500** | Site License Price
- \$9750** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.